Cancer

Valvoline Instant Oil ChangeSM supports cancer research and patient care at Dana-Farber Cancer Institute

Retrieved on: 
Tuesday, August 1, 2023

NEWTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Valvoline Instant Oil Change (VIOC) customers in New England are helping to defy cancer this summer by contributing to the Jimmy Fund through their “ A Chance for Kids & Families ® ” program.

Key Points: 
  • NEWTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Valvoline Instant Oil Change (VIOC) customers in New England are helping to defy cancer this summer by contributing to the Jimmy Fund through their “ A Chance for Kids & Families ® ” program.
  • Donate $1, $3, $5, or $7.50, in recognition of 75 years of the Jimmy Fund, at participating Valvoline Instant Oil ChangeSM locations and do your part to support Dana-Farber Cancer Institute patients and families.
  • “We are excited to participate in this program once again this year,” said Don Smith, CEO of Henley Enterprises, Inc, the largest franchisee of Valvoline Instant Oil Change .
  • “The Jimmy Fund has long been a pillar in our community, and the work they do to support cancer research and care at Dana-Farber Cancer Institute is remarkable.”
    “We are grateful for the many years of support we have received from our partners, Burger King and Valvoline Instant Oil Change, as well as the generosity of their patrons,” said Alexa Woodward, assistant vice president, corporate partnerships for Dana-Farber Cancer Institute and the Jimmy Fund.

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

Retrieved on: 
Tuesday, August 1, 2023

LONDON and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced a poster presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-oncology, which is being held from August 1-2, 2023, in Seattle, WA.

Key Points: 
  • LONDON and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced a poster presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-oncology, which is being held from August 1-2, 2023, in Seattle, WA.
  • This degree of control of timing and level of CAR expression is unprecedented.”
    Dr. Forbes continued, “The impact of precise CAR control appears to be profound.
  • The details of the poster presentation are as follows:
    Chimeric antigen receptor (CAR)-T cell therapy is a promising treatment for certain cancers.
  • Consistent with small molecule induced expression of the CAR molecule, we controlled CAR-T cell activity by the small molecule inducer.

Immutep Receives Positive Scientific Advice from European Medicines Agency

Retrieved on: 
Tuesday, August 1, 2023

SYDNEY, AUSTRALIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the continued development of eftilagimod alpha (efti), the Company's soluble LAG-3 protein and first-in-class MHC Class II agonist.

Key Points: 
  • SYDNEY, AUSTRALIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the continued development of eftilagimod alpha (efti), the Company's soluble LAG-3 protein and first-in-class MHC Class II agonist.
  • In May 2023, Immutep requested scientific advice from the EMA regarding future development of efti, and in particular whether further toxicity studies would be required before the Company could seek marketing authorisation for efti in Europe.
  • Similar advice was received from the US Food and Drug Administration (FDA) as it relates to a potential future Biologics License Application (BLA).
  • Immutep continues to be encouraged with its constructive interaction with regulatory agencies regarding its expanding late-stage clinical pipeline with efti.

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Retrieved on: 
Tuesday, August 1, 2023

CARLSBAD, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s IND application for QN-302, a potential best-in-class small molecule G-Quadruplex (G4)-selective transcription inhibitor. Based on this clearance, the Company plans to initiate the Phase 1 clinical trial in the second half of 2023 and will enroll patients with advanced or metastatic solid tumors.

Key Points: 
  • Based on this clearance, the Company plans to initiate the Phase 1 clinical trial in the second half of 2023 and will enroll patients with advanced or metastatic solid tumors.
  • Michael Poirier, Qualigen's Chairman and CEO, commented, “This is a pivotal milestone for our therapeutics pipeline as it transitions us into a clinical-stage company.
  • The IND clearance for QN-302 brings us closer to our objective of developing best in class treatments that can potentially provide new therapeutic options for patients with advanced or metastatic solid tumors.
  • The Company anticipates the dosing of at least 24 patients in the Phase 1 trial can be completed in 2024, funded in part by proceeds received by the divestiture of the Company’s diagnostics business in July 2023.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day

Retrieved on: 
Tuesday, August 1, 2023

Providence, RI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- On World Lung Cancer Day, Ocean Biomedical, Inc. (NASDAQ: OCEA) is sharing details of its multi-pronged Lung Cancer Program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. He and his team have revealed that Chitinase 3-like-1 (CHi3L1) is a master regulator that inhibits antitumor immune responses. Ocean Biomedical’s lung cancer program is advancing several approaches to reversing immune system suppression caused by CHi3L1 alone and in combination with other immunotherapy pathways. These programs suppress primary and metastatic tumor growth in multiple animal models and have potential use in multiple forms of visceral cancers. In recent studies, Ocean Biomedical’s programs have demonstrated up to 95% reduction in primary and metastatic tumor burden in mouse models of lung cancer.

Key Points: 
  • Ocean Biomedical’s first-in-class anti-CHi3L1 therapeutic immunotherapy program has shown compounding efficacy in multiple lung cancer models while simultaneously inhibiting multiple oncogenic pathways, including hard-to-treat Non-Small Cell Lung Cancer (NSCLC).
  • Providence, RI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- On World Lung Cancer Day, Ocean Biomedical, Inc .
  • In recent studies, Ocean Biomedical’s programs have demonstrated up to 95% reduction in primary and metastatic tumor burden in mouse models of lung cancer.
  • In total, Ocean Biomedical’s oncology platform has garnered 27 issued or pending patents, already covering ‘method of use’ in nine unique cancers, including prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma, and lung cancer.

Five Local Builders Unite to Construct Five Homes Benefiting St. Jude Children’s Research Hospital®

Retrieved on: 
Tuesday, August 1, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230801882222/en/
    (L-R:) Jody Alumbaugh, WillowTree Custom Homes; Nicholas Smith, Kensington Custom Homes; John Webb, Heritage Homes; Paul Moss, Beckett Graham Luxury Homes Builders; Brandon Tatta, Heritage Homes; Jon Atwood, Atwood Custom Homes (Photo: Business Wire)
    Participating builders include Atwood Custom Homes , Beckett Graham, Heritage Homes , Kensington Custom Homes, WillowTree Custom Homes , who will each donate $200,000 to St. Jude as part of this pilot project.
  • Prospective homeowners will have the chance to purchase these remarkable homes, with the proceeds benefiting St. Jude families.
  • Visit St. Jude Inspire to discover powerful St. Jude stories of hope, strength, love and kindness.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

Northwell Health is New York’s most awarded health system by U.S. News

Retrieved on: 
Tuesday, August 1, 2023

Two other Northwell hospitals also placed in the top 10 in state rankings, and dozens of programs across the health system were also ranked incredibly well.

Key Points: 
  • Two other Northwell hospitals also placed in the top 10 in state rankings, and dozens of programs across the health system were also ranked incredibly well.
  • View the full release here: https://www.businesswire.com/news/home/20230801769477/en/
    Dozens of Northwell specialty programs were ranked among the best in the nation by U.S. News & World Report.
  • “We are proud to see Northwell recognized as New York State’s most-awarded health system.
  • The health system has more hospitals ranked as the top in the state, and has more specialties ranked nationally as well.

The Scleroderma Research Foundation (SRF) Launches Conquest Trial Platform to Address Critical Issues in Clinical Development and Enable Advances in Scleroderma Therapeutics

Retrieved on: 
Tuesday, August 1, 2023

This groundbreaking effort, conceived and led by the SRF, will enroll patients across more than 130 centers in more than 22 countries. CONQUEST offers advantages to all stakeholders -- patients, physician, and drug innovators -- and provides for a seamless transition to a global Phase 3 trial, investigation of a drug’s activity in a wide range of genetic backgrounds, as well as rapid patient enrollment. By assembling a global network of high-performing centers that are dedicated to treating scleroderma, the SRF and its pharmaceutical partners expect to make enduring contributions to the scleroderma community by creating an ecosystem designed to enable success in new drug development.

Key Points: 
  • The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Sanofi will contribute the first experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF.
  • In the future, the CONQUEST platform will be expanded to address other manifestations of scleroderma.
  • Luke Evnin, Ph.D., Chairman of the Scleroderma Research Foundation, commented, “Our commitment to innovation in scleroderma spans basic, translational, and clinical research.
  • The initial run of CONQUEST is expected to enroll approximately 400 patients and trial initiation is targeted for Q4 2023.

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test

Retrieved on: 
Tuesday, August 1, 2023

The first patent application recently allowed relates to COVID and other neutralizing antibody (Nab) testing and treatment.

Key Points: 
  • The first patent application recently allowed relates to COVID and other neutralizing antibody (Nab) testing and treatment.
  • The allowance confirms that AXIM was a pioneer in developing a rapid point of care Nab test and its novelty.
  • Additionally, the company was notified by the USPTO of a second patent allowance for systems and methods for rapid diagnostic for various cancers.
  • 1 Utility Patent Application
    The invention relates to a Rapid Point of Care test for Human Monomeric Lacritin.

Terumo Blood and Cell Technologies' Reveos® Automated Whole Blood Processing System Cleared by FDA for U.S. Commercial Use

Retrieved on: 
Tuesday, August 1, 2023

LAKEWOOD, Colo., Aug. 1, 2023 /PRNewswire/ -- Terumo Blood and Cell Technologies (Terumo BCT) announces U.S. Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System, the first whole blood automation device available in the U.S. that processes whole blood into platelets and other components in a single centrifugation cycle. Automated processing of whole blood on the Reveos system, the only device of its kind globally, will enhance the blood and platelet supply for patients in the U.S.

Key Points: 
  • [2] FDA's clearance of the automated Reveos system gives blood centers the added capacity to collect platelets from existing whole blood donations efficiently.
  • In Reveos, Terumo BCT brings to the U.S. a platform with an established track record following deployment in 52 countries over the past decade.
  • Reveos is the only automated device to process whole blood into platelets, plasma and red blood cell (RBC) components in a single centrifugation cycle.
  • By automating whole blood processing, Reveos can reduce the working hours needed by laboratory staff by up to 30%.